Breaking News

Gilead To Acquire Arresto Biosciences

Gilead Sciences has signed an agreement to acquire Arresto Biosciences for $225 million and potential payments based on certain sales levels.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences has signed an agreement to acquire Arresto Biosciences for $225 million and potential payments based on certain sales levels. The deal is expected to close in 1Q11, subject to certain closing conditions. Arresto is development-stage biopharma company focused on medicines to treat fibrotic diseases and cancer. Its lead product, AB0024, is a humanized monoclonal antibody (mAb) targeting the human lysyl oxidase-like-2 (LOXL2) protein currently in a Phase I study in patients with ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters